Project Grant K01AI194968
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$209K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of California, Davis. The grant, titled "OPTIMAL T-CELL SUPPORT FOR HIV NEUTRALIZING ANTIBODY INDUCTION TO FUSION PEPTIDE-INCLUSIVE REGIMENS (OPTI-FLIP)", will fund the development of an HIV vaccine regimen that elicits cooperative interactions between fusion peptide-directed...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $340,712 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Rochester. The grant, titled "Evaluating the Role of Monocytes in the Development of an Effective HIV Vaccine Response", aims to investigate the role of monocyte subpopulations in regulating the antibody response to HIV vaccines. The research project, scheduled for completion by June 30, 2027,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $742,463 in funding to the University of Washington to conduct research on HIV envelope glycoprotein vaccines. The goal is to leverage sequence diversity and glycan holes in naturally occurring HIV envelope proteins to design vaccine immunogens that can induce broadly neutralizing antibodies. The research approach involves in silico modeling,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $410,813 Project Grant under CFDA 93.855 Allergy and Infectious Diseases Research to the University of Hawaii at Manoa. The research aims to design and test novel immunogens capable of guiding the evolution of the VRC01 B-cell lineage towards a mature phenotype that can produce broadly neutralizing antibodies against HIV. Specific objectives include in vitro testing of prototype and engineered immunogens for binding...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $242,310 to Emory University to study how genetic diversity in the immunoglobulin heavy chain locus impacts the development of neutralizing antibodies against the HIV envelope protein. The project aims to: 1) Identify polymorphisms in rhesus macaques vaccinated with the BG505 SOSIP.664 HIV immunogen that are associated with differential...